STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-14

Study Completion Date

2021-03-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine whether the combination of gemcitabine/carboplatin with hydroxychloroquine (HCQ) is associated with an improved clinical outcome (progression free and overall survival) compared with chemotherapy alone in patients with small cell lung cancer (SCLC)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer

NCT00728845

Lung Cancer

TERMINATED PHASE1/PHASE2

A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC

NCT04063163

Extensive Stage Small Cell Lung Cancer

COMPLETED PHASE3

SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013

NCT02738346

Small Cell Lung Cancer

UNKNOWN PHASE3

Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00070486

Lung Cancer

COMPLETED PHASE2

Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults

NCT00043927

Small Cell Lung Cancer

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicentre, randomised, phase II trial which aims to compare the combination of hydroxychloroquine and gemcitabine/carboplatin versus standard carboplatin/etoposide chemotherapy, as first line treat in patients with stage IV disease.

The standard first line chemotherapy treatment remains a platinum-based chemotherapy and this has been unchanged for 20 years. Novel active treatment approaches are urgently needed to improve survival in SCLC.

Patients are randomised to one of two treatment arms; carboplatin/etoposide or gemcitabine/carboplatin/hydroxychloroquine.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Arm

* IV carboplatin AUC5 (area under curve) on Day1
* IV etoposide 120mg/m2 Day 1, followed by oral etoposide 100mg BD (twice daily) on Day 2 and Day 3

Group Type ACTIVE_COMPARATOR

Carboplatin

Intervention Type DRUG

Chemotherapy

Etoposide

Intervention Type DRUG

Chemotherapy

Investigational Arm

* IV gemcitabine 1200mg/m2 on Day 1 and Day 8
* IV carboplatin AUC5 on Day 1
* Oral HCQ will be taken at a dose of 400mg BD from day 1 of cycle 1 (maximum of 30 months)

Group Type EXPERIMENTAL

Gemcitabine

Intervention Type DRUG

Chemotherapy

Carboplatin

Intervention Type DRUG

Chemotherapy

Hydroxychloroquine

Intervention Type DRUG

Maintenance Agent

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gemcitabine

Chemotherapy

Intervention Type DRUG

Carboplatin

Chemotherapy

Intervention Type DRUG

Etoposide

Chemotherapy

Intervention Type DRUG

Hydroxychloroquine

Maintenance Agent

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically or cytologically confirmed SCLC
* Stage IV disease
* Performance status ECOG 0-2
* Life expectancy \>8 weeks
* Age 18 or over
* Willing and able to give informed consent
* Patient considered able to tolerate chemotherapy
* Adequate renal function - defined by GFR ≥50mL/min as measured by EDTA or C\&G
* Adequate bone marrow reserve: Absolute neutrophil count ≥1.5 x 109/L, haemoglobin ≥90 g/L, platelet count ≥100 x 109/L
* Negative pregnancy test for WCBP
* Highly effective contraception is mandatory for all patients of reproductive potential
* At least one site of measurable disease (target lesion) for RECIST 1.1 evaluation
* Hypersensitivity or history of severe allergic reaction to any of the IMPs
* Able to swallow medication

Exclusion Criteria

* Mixed cell histology (i.e. NSCLC and SCLC)
* Prior macular degeneration or diabetic retinopathy
* History of glaucoma
* Patients with abnormal LFTs (ALP, ALT/AST\*) that are ≥3 x ULN (≥5 x ULN for patients with liver metastases)
* Patients with abnormal bilirubin levels that are ≥1.5 x ULN
* Prior treatment for this disease e.g. chemotherapy, surgery, radiotherapy (except palliative radiotherapy to bone metastases)
* Documented side effects to chloroquine or related agents
* Treatment with chloroquine or related agents within the last year prior to randomisation
* Evidence of significant medical condition or laboratory finding which, in the opinion of the investigator, makes it undesirable for the patient to participate in the trial
* Previous medical history of prolonged QT interval
* A history of prior malignant tumour, unless the patient has been without evidence of disease for at least 3 years or the tumour was a non-melanoma skin tumour or early cervical cancer
* Patients with symptomatic brain metastases
* Women who are breastfeeding
* Concurrent cytochrome P450 enzyme-inducing anticonvulsant drugs e.g. phenytoin, carbamazepine, phenobarbital, primidone or oxcarbazepine
* Patients who are unable to have their digoxin levels regularly monitored

* if both ALT and AST performed then both need to be recorded

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No